Advanced Biomimetic Sensors (ABS), Inc. is a pioneer in the development and commercialization of innovative reagentless diagnostic medical devices. These devices can be both hand-held and implantable for continuing monitoring. ABS intends to develop prototype devices to provide the market with a new generation of more accurate, sensitive, less expensive and pain-free medical devices, such as glucose monitoring for diabetics, especially suitable for diabetic children.
ABS was founded in 2006 by Dr. Ellen Chen. She brings deep passion to her research - a passion born out of compassion. She founded her company with the intent to use technology to reduce the suffering endured by patients, and by children in particular.
Dr. Chen was a Principal Investigator at the Center for Devices and Radiological Health (CDRH) at the U.S. Food and Drug Administration (US FDA). During her tenure, she was a Project Manager responsible for conducting a multiple-center clinical study regarding the development of an industry standard for evaluation of the performance of self-monitoring blood glucose (SMBG) meters. Dr. Chen’s research team received the Special Recognition Award from the FDA in 2001. The Award states: For outstanding scientific expertise and leadership in addressing critical issues impacting the health of 16 million diabetics who use SMBG devices. The research team consisted of a team from the Clinical Center in NIH, a team from the Johns Hopkins Clinical Center and a team from the University of Maryland Clinical System.